FDA approves antidepressant nasal spray

FDA-approved nasal spray for severe depression can lead to remission
The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in people who have not responded to at least two oral antidepressants.
What to Know About the New Nasal Spray for Tough Depression
CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more medication.
FDA approves first-of-its-kind nasal spray for severe depression
Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD, and similar psychiatric conditions.
New Nasal Spray to Treat Depression Gets FDA Approval
The U.S. Food and Drug Administration has approved a nasal spray to treat depression—the first-ever stand-alone medication for patients with severe depression. Johnson & Johnson said patients who use the nasal spray Spravato—which is made from the drug esketamine—may see improvements in depressive symptoms in as little as 24 hours.
FDA OKs Esketamine Nasal Spray Monotherapy for Resistant Depression
The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not responded to at least two oral antidepressants.
Ketamine-Derived Nasal Spray Approved as Standalone Treatment for Tough Depression Cases
An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a standalone therapy for cases of depression that haven’t responded to other options.
FDA approves Johnson & Johnson’s ketamine-derived nasal spray for depression as stand-alone treatment
The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult population.
Can a Nasal Spray Really Help Treat Depression? Here's What to Know About Spravato
Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.
FDA approves standalone nasal spray to treat depression
A one-time nasal spray has been approved by the Food and Drug Administration as a standalone treatment for depression.
Pharmabiz21h
Lupin receives US FDA approval for generic Atrovent nasal spray, 0.06%
Lupin receives US FDA approval for generic Atrovent nasal spray, 0.06%: Our Bureau,Mumbai Tuesday, January 28, 2025, 17:30 Hrs [IST] Global pharma major Lupin Limited (Lupin) anno ...
Monthly Prescribing Reference1d
Nasal Spray Formulation of Bumetanide Under FDA Review
The NDA is supported by data from a clinical trial that compared the absorption and efficacy of the nasal treatment with oral and IV bumetanide in 68 healthy adults.
Corstasis Therapeutics Inc. Announces FDA Acceptance of New Drug Application for Bumetanide Nasal Spray
"We are pleased the FDA has accepted our NDA for Bumetanide Nasal Spray," said Benjamin Esque, CEO of Corstasis Therapeutics ...